Rongchang Bio forecasts 2026 first-half revenue to surge 433% to 5.85 billion yuan
The biotech expects a swing to profit after losses a year earlier, helped by stronger sales of telitacicept and disitamab vedotin and an AbbVie licensing deal for RC148.